Dembitz V and Gallipoli P (2021). The Role of Metabolism in the Development of Personalized Therapies in Acute Myeloid Leukemia. Frontiers in Oncology  vol. 11, 10.3389/fonc.2021.665291

Hughes CFM, Gallipoli P and Agarwal R (2021). Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome. Elsevier  Pathology  10.1016/j.pathol.2021.01.005

Forte D, García-Fernández M, Sánchez-Aguilera A, Stavropoulou V, Fielding C, Martín-Pérez D, López JA, Costa ASH, Tronci L, Nikitopoulou E, Barber M, Gallipoli P, Marando L, Fernández de Castillejo CL, Tzankov A, Dietmann S, Cavo M, Catani L, Curti A, Vázquez J, Frezza C, Huntly BJ, Schwaller J and Méndez-Ferrer S (2020). Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy. Cell Metabolism  vol. 32, (5) 829-843.e9. 10.1016/j.cmet.2020.09.001

Castelli R, Bergamaschini L, Teatini T, Cilumbriello L, Schiavon R, Gallipoli P and Deliliers GL (2020). Does Outcome/Survival of Patients With Myelodysplastic Syndromes Should Be Predicted by Reduced Levels of ADAMTS-13? Results From a Pilot Study. Clinical Lymphoma, Myeloma and Leukemia  vol. 20, (8) e461-e467. 10.1016/j.clml.2019.12.016

Horne GA, Stobo J, Kelly C, Mukhopadhyay A, Latif AL, Dixon-Hughes J, McMahon L, Cony-Makhoul P, Byrne J, Smith G, Koschmieder S, BrÜmmendorf TH, Schafhausen P, Gallipoli P, Thomson F, Cong W, Clark RE, Milojkovic D, Helgason GV, Foroni L, Nicolini FE, Holyoake TL and Copland M (2020). A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia  vol. 34, (7) 1775-1786. 10.1038/s41375-019-0700-9

Sasca D, Yun H, Giotopoulos G, Szybinski J, Evan T, Wilson NK, Gerstung M, Gallipoli P, Green AR, Hills R, Russell N, Osborne CS, Papaemmanuil E, Göttgens B, Campbell P and Huntly BJP (2019). Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies. Blood  vol. 134, (24) 2195-2208. 10.1182/blood.2019001553

Claudiani S, Metelli S, Kamvar R, Szydlo R, Khan A, Byrne J, Gallipoli P, Bulley SJ, Horne GA, Rothwell K, Copland M, Clark RE, Khorashad JS, Foroni L, Milojkovic D and Apperley JF (2019). Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML). Blood  vol. 134, (1) 10.1182/blood-2019-131500

Basheer F, Giotopoulos G, Meduri E, Yun H, Mazan M, Sasca D, Gallipoli P, Marando L, Gozdecka M, Asby R, Sheppard O, Dudek M, Bullinger L, Döhner H, Dillon R, Freeman S, Ottmann O, Burnett A, Russell N, Papaemmanuil E, Hills R, Campbell P, Vassiliou GS and Huntly BJP (2019). Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. Journal of Experimental Medicine  vol. 216, (4) 966-981. 10.1084/jem.20181276

Gallipoli P and Huntly BJP (2019). Prognostic models turn the heat(it)up on FLT3 ^ITD -mutated AML. Clinical Cancer Research  vol. 25, (2) 460-462. 10.1158/1078-0432.CCR-18-3146

Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL and Bergamaschini L (2019). Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. Journal of Thrombosis and Thrombolysis  vol. 47, (1) 155-156. 10.1007/s11239-018-1773-4

Gallipoli P and Huntly BJP (2019). Histone modifiers are oxygen sensors. Science  vol. 363, (6432) 1148-1149. 10.1126/science.aaw8373

Tzelepis K, De Braekeleer E, Aspris D, Barbieri I, Vijayabaskar MS, Liu WH, Gozdecka M, Metzakopian E, Toop HD, Dudek M, Robson SC, Hermida-Prado F, Yang YH, Babaei-Jadidi R, Garyfallos DA, Ponstingl H, Dias JML, Gallipoli P, Seiler M, Buonamici S, Vick B, Bannister AJ, Rad R, Prinjha RK, Marioni JC, Huntly B, Batson J, Morris JC, Pina C and Bradley A (2018). SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4. Nature Communications  vol. 9, (1) 10.1038/s41467-018-07620-0

Gallipoli P (2018). JAK of all trades: Ruxolitinib as a new therapeutic option for CML patients. Leukemia Research  vol. 75, 71-72. 10.1016/j.leukres.2018.10.010

Gallipoli P and Huntly BJP (2018). Novel epigenetic therapies in hematological malignancies: Current status and beyond. Seminars in Cancer Biology  vol. 51, 198-210. 10.1016/j.semcancer.2017.07.005

Gallipoli P, Giotopoulos G, Tzelepis K, Costa ASH, Vohra S, Medina-Perez P, Basheer F, Marando L, Lisio LD, Dias JML, Yun H, Sasca D, Horton SJ, Vassiliou G, Frezza C and Huntly BJP (2018). Glutaminolysis is a metabolic dependency in FLT3 ^ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition. Blood  vol. 131, (15) 1639-1653. 10.1182/blood-2017-12-820035

Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL and Bergamaschini L (2018). High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation. Journal of Thrombosis and Thrombolysis  vol. 45, (1) 106-113. 10.1007/s11239-017-1566-1

Tarafdar A, Hopcroft LE, Gallipoli P, Pellicano F, Cassels J, Hair A, Korfi K, Jørgensen HG, Vetrie D, Holyoake TL and Michie AM (2016). CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood  10.1182/blood-2016-09-742049

Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, Mupo A, Grinkevich V, Li M, Mazan M, Gozdecka M, Ohnishi S, Cooper J, Patel M, McKerrell T, Chen B, Domingues AF, Gallipoli P, Teichmann S, Ponstingl H, McDermott U, Saez-Rodriguez J, Huntly BJP, Iorio F, Pina C, Vassiliou GS and Yusa K (2016). A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia. Cell Reports  vol. 17, (4) 1193-1205. 10.1016/j.celrep.2016.09.079

Scott MT, Korfi K, Saffrey P, Hopcroft LE, Kinstrie R, Pellicano F, Guenther C, Gallipoli P, Cruz M, Dunn K, Jorgensen HG, Cassels JE, Hamilton A, Crossan A, Sinclair A, Holyoake TL and Vetrie D (2016). Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition. American Association For Cancer Research  Cancer Discovery  vol. 6, (11) 1248-1257. 10.1158/2159-8290.CD-16-0263

Gidaro A, Deliliers GL, Gallipoli P, Arquati M, Wu MA and Castelli R (2016). Laboratory and clinical risk assessment to treat myelodysplatic syndromes. Clinical Chemistry and Laboratory Medicine  vol. 54, (9) 1411-1426. 10.1515/cclm-2015-0789

Giotopoulos G, Chan WI, Horton SJ, Ruau D, Gallipoli P, Fowler A, Crawley C, Papaemmanuil E, Campbell PJ, Göttgens B, Van Deursen JM, Cole PA and Huntly BJP (2016). The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia. Oncogene  vol. 35, (3) 279-289. 10.1038/onc.2015.92

Castelli R, Pantaleo G, Gallipoli P, Gidaro A, Arquati M, Wu MA and Lambertenghi Deliliers G (2015). Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma. Anti-Cancer Drugs  vol. 26, (10) 1078-1082. 10.1097/CAD.0000000000000285

Giotopoulos G, van der Weyden L, Osaki H, Rust AG, Gallipoli P, Meduri E, Horton SJ, Chan WI, Foster D, Prinjha RK, Pimanda JE, Tenen DG, Vassiliou GS, Koschmieder S, Adams DJ and Huntly BJP (2015). A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression. Journal of Experimental Medicine  vol. 212, (10) 1551-1569. 10.1084/jem.20141661

Gallipoli P, Giotopoulos G and Huntly BJP (2015). Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia. Therapeutic Advances in Hematology  vol. 6, (3) 103-119. 10.1177/2040620715577614

Hopcroft LEM, Calderhead B, Gallipoli P, Holyoake TL and Girolami MA (2015). Bayesian inference for model selection: An application to aberrant signalling pathways in chronic myeloid leukaemia. Systems Genetics: Linking Genotypes and Phenotypes  10.1017/CBO9781139012751.009

Gallipoli P, Cook A, Rhodes S, Hopcroft L, Wheadon H, Whetton AD, Jørgensen HG, Bhatia R and Holyoake TL (2014). JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34⁺ cells in vitro and in vivo. Blood  vol. 124, (9) 1492-1501. 10.1182/blood-2013-12-545640

Colombo R, Gallipoli P and Castelli R (2014). Thrombosis and hemostatic abnormalities in hematological malignancies. Clinical Lymphoma, Myeloma and Leukemia  vol. 14, (6) 441-450. 10.1016/j.clml.2014.05.003

Castelli R, Deliliers GL, Colombo R, Moreo G, Gallipoli P and Pantaleo G (2014). Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function. Annals of Hematology  vol. 93, (9) 1523-1529. 10.1007/s00277-014-2070-8

Gallipoli P, Stobo J, Heaney N, Nicolini FE, Clark R, Wilson G, Tighe J, Mclintock L, Hughes T, Michor F, Paul J, Drummond M and Holyoake TL (2013). Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. British Journal of Haematology  vol. 163, (5) 674-676. 10.1111/bjh.12532

Giotopoulos G, Chan W-I, Ruau D, Gallipoli P, Fowler A, Göttgens B, Van Deursen J, Cole P and Huntly B (2013). The Epigenetic Regulators CBP and p300 Facilitate Leukemogenesis and Represent Therapeutic Targets In Acute Myeloid Leukemia (AML). Blood  vol. 122, (21) 3732-3732. 10.1182/blood.v122.21.3732.3732

Chen M, Gallipoli P, Degeer D, Sloma I, Forrest DL, Chan M, Lai D, Jorgensen H, Ringrose A, Wang HM, Lambie K, Nakamoto H, Saw KM, Turhan A, Arlinghaus R, Paul J, Stobo J, Barnett MJ, Eaves A, Eaves CJ, Holyoake TL and Jiang X (2013). Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. Journal of The National Cancer Institute  vol. 105, (6) 405-423. 10.1093/jnci/djt006

Mcilwaine L, Parker A, Sandilands G, Gallipoli P and Leach M (2013). Neutrophil-specific granule deficiency. British Journal of Haematology  vol. 160, (6) 10.1111/bjh.12207

Gallipoli P, Pellicano F, Morrison H, Laidlaw K, Allan EK, Bhatia R, Copland M, Jørgensen HG and Holyoake TL (2013). Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation. Blood  vol. 122, (19) 3335-3339. 10.1182/blood-2013-02-485607

Shah M, Gallipoli P, Lyons J, Holyoake T and Jørgensen H (2012). Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro. Blood Cells, Molecules, and Diseases  vol. 48, (3) 199-201. 10.1016/j.bcmd.2012.01.005

Gallipoli P, Abraham SA and Holyoake TL (2011). Hurdles Toward a Cure for CML: The CML Stem Cell. Hematology/Oncology Clinics of North America  vol. 25, (5) 951-966. 10.1016/j.hoc.2011.09.001

Gallipoli P, Shepherd P, Irvine D, Drummond M and Holyoake T (2011). Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: Results from a West of Scotland and Lothian population study. British Journal of Haematology  vol. 155, (1) 128-130. 10.1111/j.1365-2141.2011.08653.x

DeGeer D, Gallipoli P, Chen M, Sloma I, Jorgensen H, Forrest D, Lambie K, Nakamoto H, Saw KM, Chan M, Newmarch K, Zhou L, Turhan AG, Arlinghaus RB, Eaves AC, Eaves CJ, Holyoake TL and Jiang X (2010). Combined Targeting of BCR-ABL and JAK2 with ABL and JAK2 Inhibitors Is Effective Against CML Patients' Leukemic Stem/Progenitor Cells. Blood  vol. 116, (21) 3404-3404. 10.1182/blood.v116.21.3404.3404

Hamilton A, Gallipoli P, Nicholson E and Holyoake TL (2010). Targeted therapy in haematological malignancies. Journal of Pathology  vol. 220, (4) 404-418. 10.1002/path.2669

Gallipoli P, Clark A and Leach M (2009). The evolving management of a rare lymphoproliferative disorder-T-cell prolymphocytic leukemia. American Journal of Hematology  vol. 84, (11) 750-753. 10.1002/ajh.21498

Gallipoli P, Tang A and Leach M (2009). Cortical blindness due to sagittal sinus thrombosis in acute lymphoblastic leukaemia. British Journal of Haematology  vol. 145, (3) 10.1111/j.1365-2141.2008.07462.x

Gallipoli P, Drummond M and Leach M (2009). Hemophagocytosis and relapsed peripheral T-cell lymphoma. European Journal of Haematology  vol. 82, (3) 10.1111/j.1600-0609.2008.01167.x

Gallipoli P (2009). Pseudotumour cerebri as a manageable side effect of prolonged all-trans retinoic acid therapy in an adult patient with acute promyelocytic leukaemia. European Journal of Haematology  vol. 82, (3) 242-243. 10.1111/j.1600-0609.2008.01185.x

Fyfe AJ and Gallipoli P (2009). Multiple splenic calcifications: Images in haematology. British Journal of Haematology  vol. 144, (6) 10.1111/j.1365-2141.2008.07420.x

Gallipoli P and Leach M (2007). Gingival infiltration in acute monoblastic leukaemia. British Dental Journal  vol. 203, (9) 507-509. 10.1038/bdj.2007.994

Finelli C, Gallipoli P, Celentano E, Cacace G, Saldalamacchia G, De Caprio C, Contaldo F and Pasanisi F (2006). Assessment of physical activity in an outpatient obesity clinic in southern Italy: Results from a standardized questionnaire. Nutrition, Metabolism and Cardiovascular Diseases  vol. 16, (3) 168-173. 10.1016/j.numecd.2005.05.002

Gallipoli P (2002). Medical education: Britain versus Italy. The Bmj  vol. 324, (Suppl S2) 10.1136/sbmj.020232

Gallipoli P (2002). Glasgow: a very interesting place. The Bmj  vol. 324, (Suppl S2) 10.1136/sbmj.020231

Clark JA, Deutch AY, Gallipoli PZ and Amara SG (1992). Functional expression and CNS distribution of a β-alanine-sensitive neuronal GABA transporter. Neuron  vol. 9, (2) 337-348. 10.1016/0896-6273(92)90172-A